Barclays analyst James Gordon raised the firm’s price target on AstraZeneca (AZN) to 16,500 GBp from 14,000 GBp and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca announces results of Saphnelo were statistically significant
- Kennedy scales back number of vaccines recommended for children, NYT says
- AstraZeneca removed from European Conviction List at Goldman Sachs
- Mereo Biopharma Stock (MREO) Collapses over 90% after Failed Trials
- MSFT, CRM, ORCL: Why Evercore Names These 3 Software Stocks as ‘Top Picks for 2026’